Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
News|Articles|September 30, 2024
IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer
Author(s)Russ Conroy
Fact checked by: Harrison Widelitz
Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.
Advertisement
Advertisement
Intensity-modulated radiation therapy (IMRT) and proton beam therapy yielded comparable quality of life (QOL) outcomes and effective tumor control among patients with localized prostate cancer, according to findings from the phase 3 Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) trial (NCT01617161) presented in a press briefing at the
Related to this article
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Advertisement
Advertisement